OBJECTIVE: An unstructured treatment interruption in children with perinatally acquired HIV infection is an issue with unresolved significance. The objective of this study was to investigate the actual prevalence and clinical outcomes of a treatment interruption in children and adolescents with perinatally acquired HIV-1 infection. METHODS: Clinical data were analyzed for 72 children and adolescents who had HIV-1 infection and stopped their medications at 4 academic centers in the United States between January 2000 and September 2004. RESULTS: Among 405 patients with perinatal HIV-1 infection, 72 (17.8%) experienced a treatment interruption during the observation period. The mean age of patients at the time of the treatment interruption was 12.8 years, and the mean length of the treatment interruption was 14 months. Medication fatigue was the most common reason for a treatment interruption. The CD4+ T-cell percentage nadir before the treatment interruption did not predict CD4+ T-cell percentage declines during the treatment interruption; however, the CD4+ T-cell percentage gain from nadir to the time of the treatment interruption predicted CD4+ T-cell percentage declines during the treatment interruption. During the median follow-up of 19 months (range: 6-48 months), 48 (67%) patients resumed antiretroviral medications. As expected, there was a continuous CD4+ T-cell percentage decrease and plasma HIV-1 RNA increase during the observation period. Overall, 7 (10%) patients were admitted to the hospital; 2 (3%) patients experienced an AIDS-defining illness. CONCLUSIONS: An unstructured treatment interruption seems to be a major issue for youth with perinatally acquired HIV-1 infection. Patients who experienced the greatest rise in CD4+ T-cell percentage on treatment had the largest CD4+ T-cell percentage decline after the treatment interruption. Close monitoring is required when a treatment interruption occurs in children and adolescents with HIV infection.
OBJECTIVE: An unstructured treatment interruption in children with perinatally acquired HIV infection is an issue with unresolved significance. The objective of this study was to investigate the actual prevalence and clinical outcomes of a treatment interruption in children and adolescents with perinatally acquired HIV-1 infection. METHODS: Clinical data were analyzed for 72 children and adolescents who had HIV-1 infection and stopped their medications at 4 academic centers in the United States between January 2000 and September 2004. RESULTS: Among 405 patients with perinatal HIV-1 infection, 72 (17.8%) experienced a treatment interruption during the observation period. The mean age of patients at the time of the treatment interruption was 12.8 years, and the mean length of the treatment interruption was 14 months. Medication fatigue was the most common reason for a treatment interruption. The CD4+ T-cell percentage nadir before the treatment interruption did not predict CD4+ T-cell percentage declines during the treatment interruption; however, the CD4+ T-cell percentage gain from nadir to the time of the treatment interruption predicted CD4+ T-cell percentage declines during the treatment interruption. During the median follow-up of 19 months (range: 6-48 months), 48 (67%) patients resumed antiretroviral medications. As expected, there was a continuous CD4+ T-cell percentage decrease and plasma HIV-1 RNA increase during the observation period. Overall, 7 (10%) patients were admitted to the hospital; 2 (3%) patients experienced an AIDS-defining illness. CONCLUSIONS: An unstructured treatment interruption seems to be a major issue for youth with perinatally acquired HIV-1 infection. Patients who experienced the greatest rise in CD4+ T-cell percentage on treatment had the largest CD4+ T-cell percentage decline after the treatment interruption. Close monitoring is required when a treatment interruption occurs in children and adolescents with HIV infection.
Authors: Gabriela Patten; Michael Schomaker; Mary-Ann Davies; Helena Rabie; Gert van Zyl; Karl Technau; Brian Eley; Andrew Boulle; Russell B Van Dyke; Kunjal Patel; Nosisa Sipambo; Robin Wood; Frank Tanser; Janet Giddy; Mark Cotton; James Nuttall; Gadija Essack; Brad Karalius; George Seage; Shobna Sawry; Matthias Egger; Lee Fairlie Journal: Pediatr Infect Dis J Date: 2019-04 Impact factor: 2.129
Authors: George K Siberry; Kunjal Patel; Russell B Van Dyke; Rohan Hazra; Sandra K Burchett; Stephen A Spector; Mary E Paul; Jennifer S Read; Andrew Wiznia; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Adam W Bartlett; Pagakrong Lumbiganon; Nia Kurniati; Tavitiya Sudjaritruk; Thahira J Mohamed; Rawiwan Hansudewechakul; Penh S Ly; Khanh H Truong; Thanyawee Puthanakit; Lam V Nguyen; Kulkanya Chokephaibulkit; Viet C Do; Nagalingeswaran Kumarasamy; Nik Khairulddin Nik Yusoff; Moy S Fong; Dewi K Watu; Revathy Nallusamy; Annette H Sohn; Matthew G Law Journal: J Adolesc Health Date: 2019-08-05 Impact factor: 5.012
Authors: L A Cysique; F Vaida; S Letendre; S Gibson; M Cherner; S P Woods; J A McCutchan; R K Heaton; R J Ellis Journal: Neurology Date: 2009-05-27 Impact factor: 9.910